Pharmaceutical Compliance Monitor

pharmacompliancemonitor.com

Pharma Compliance Monitor (PCM) is only publication that spotlights regulatory and compliance news and developments for the pharmaceutical and biotechnology communities. PCM’s ongoing goal is to create a place where pharmaceutical and biotechnology professionals and executives can go to stay informed, interact and learn. Read by senior compliance professionals and executives at many of the largest research-based pharmaceutical and biotechonology manufacturers, PCM speaks to the decision maker faced with making mission critical choices that anchor best-in-class corporate compliance and ethics programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR STERILE WATER FOR INJECTION, USP

Businesswire | July 26, 2023

news image

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials. According to the FDA and the FD&C Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of steri...

Read More

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

news image

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

FIERCEPHARMAPOLITICS—GILEAD CEO SEES COVID-19 CHANGING THE DRUG PRICING CONVERSATION

Fiercepharma | May 04, 2020

news image

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. With less than six months to go until the U.S. elections, the pharma industry finds itself in a different position than expected at the start of the year. While many predicted a tense year as candidates went on the attack, the pandemic has taken the spotlight. And instead of being an easy target, pharma c...

Read More

Business Insights

MEDAVAIL ANNOUNCES PRICING OF $50 MILLION PRIVATE PLACEMENT

MedAvail | April 01, 2022

news image

MedAvail Holdings, Inc. a technology-enabled retail pharmacy company, announced it has entered into a definitive securities purchase agreement for the sale of common stock and warrants to purchase common stock in a private placement with certain institutional and other accredited investors for gross proceeds to MedAvail of $50 million, before deducting placement agent commissions and other offering expenses. Pursuant to the terms of the securities purchase agreement and following ...

Read More
news image

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR STERILE WATER FOR INJECTION, USP

Businesswire | July 26, 2023

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials. According to the FDA and the FD&C Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of steri...

Read More
news image

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More
news image

FIERCEPHARMAPOLITICS—GILEAD CEO SEES COVID-19 CHANGING THE DRUG PRICING CONVERSATION

Fiercepharma | May 04, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. With less than six months to go until the U.S. elections, the pharma industry finds itself in a different position than expected at the start of the year. While many predicted a tense year as candidates went on the attack, the pandemic has taken the spotlight. And instead of being an easy target, pharma c...

Read More
news image

Business Insights

MEDAVAIL ANNOUNCES PRICING OF $50 MILLION PRIVATE PLACEMENT

MedAvail | April 01, 2022

MedAvail Holdings, Inc. a technology-enabled retail pharmacy company, announced it has entered into a definitive securities purchase agreement for the sale of common stock and warrants to purchase common stock in a private placement with certain institutional and other accredited investors for gross proceeds to MedAvail of $50 million, before deducting placement agent commissions and other offering expenses. Pursuant to the terms of the securities purchase agreement and following ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us